Abstract:Imbalances in protein and noncoding RNA levels in vivo lead to the occurrence of many diseases. In addition to the use of small molecule inhibitors and agonists to restore these imbalances, recently emerged targeted degradation technologies provide a new direction for disease treatment. Targeted degradation technology directly degrades target proteins or RNA by utilizing the inherent degradation pathways, thereby eliminating the functions of pathogenic proteins (or RNA) to treat diseases. Compared with traditional therapies, targeted degradation technology which avoids the principle of traditional inhibitor occupation drive, has higher efficiency and selectivity, and widely expands the range of drug targets. It is one of the most promising and hottest areas for future drug development. Herein, we systematically introduced the in vivo degradation systems applied to degrader design: ubiquitin–proteasome system, lysosomal degradation system, and RNA degradation system. We summarized the development progress, structural characteristics, and limitations of novel chimeric design technologies based on different degradation systems. In addition, due to the lack of clear ligand‐binding pockets, about 80% of disease‐associated proteins cannot be effectively intervened with through traditional therapies. We deeply elucidated how to use targeted degradation technology to discover and design molecules for representative undruggable targets including transcription factors, small GTPases, and phosphatases. Overall, this review provides a comprehensive and systematic overview of targeted degradation technology‐related research advances and a new guidance for the chimeric design of undruggable targets.

Chimera induced protein degradation: PROTACs and beyond

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Chemistries of bifunctional PROTAC degraders

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Major Advances in Emerging Degrader Technologies.

Progress and Challenges of PROTAC in the Development of Anti-tumor Drugs

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

The new direction of drug development: Degradation of undruggable targets through targeting chimera technology

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs

A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

Current strategies for improving limitations of proteolysis targeting chimeras

The Present and Future of Novel Protein Degradation Technology

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy